Diagnosis of squamous intraepithelial lesions and cervical cancer based on the quantitative assessment of microRNA expression


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To estimate the possibility of differential diagnosis of the severity of cervical squamous intraepithélial lesions on the basis of quantitative assessment of microRNA expression: has-mir-22-3p, has-mir-25*-3p, and has-mir-92a-5p in cervical epithelial scrapings. Subjects and methods. The investigation enrolled 95 women aged 18 to 49 years (mean age, 32.7±0.5 years) who were divided into 4 groups: 1) 32 patients without cervical disease; 2) 31 patients with low-grade squamous intraepithelial lesion; 3) 26 patients with high-grade squamous intraepithelial lesion; 4) 6 patients with cervical cancer. For a clinical diagnosis, cytological and histological examinations, extended colposcopy, and HPV testing were used and the level of microRNA expression was measured by quantitative real-time PCR. Results. In cervical squamous intraepithelial lesions, the synthesis of mir-22 was considerably decreased and the expression of mir-92a was, on the contrary, increased. The expression of mir-25 was elevated Insignificantly. A logistic regression analysis could reveal the mir-22 and mir-92a expression thresholds that allowed the differentiation of cervical cancer with a diagnostic accuracy of more than 80% in both patients without visible abnormalities and those with squamous intraepithelial lesions. Conclusion. Along with traditional methods, the investigation permits the expression level of miRNAs, mir-22, and mir-92a to be considered as an informative molecular marker to predict the extent of involvement of the cervical epithelium in pre-cancer and cancer of the cervix uteri.

全文:

受限制的访问

作者简介

Viktoria Chernova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

PhD student

Vitaly Karnaukhov

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_karnauhov@oparina4.ru
Junior Researcher, Laboratory of Molecular Genetic Methods

Leonid Faizullin

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: l_faizullin@oparina4.ru
Cand. Sc. (Biology), Leading Researcher, Laboratory of Molecular Genetic Methods

Guldana Bairamova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: g_bairamova@oparina4.ru
doctor of medical sciences, head of the clinical work of the scientific and polyclinic department

Evgenia Kogan

I.M. Sechenov First Moscow State Medical University

Email: koganevg@gmail.com
MD, Professor, Head of the Department of Pathological Anatomy

Guranda Mzarelua

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: mzareluag@mail.ru
graduate student

Niso Nazarova

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: grab2@yandex.ru
MD, PhD, Senior Researcher

Andrey Kozachenko

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_kozachenko@oparina4.ru
leading research assistant of the gynecological department

Dmitriy Trofimov

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: d_trofimov@oparina4.ru
Doctor of Biological Sciences, Head of the Laboratory of Molecular Genetic Methods

Vera Prilepskaya

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: VPrilepskaya@mail.ru
MD, PhD, Professor, Deputy Director for Science

Gennady Sukhikh

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: g_sukhikh@oparina4.ru
Doctor of Medical Sciences, Academician of the Russian Academy of Sciences, Director

参考

  1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA: Cancer J. Clin. 2015; 65(2): 87-108.
  2. Bernard E., Pons-Salort M., Favre M., Heard I., Delarocque-Astagneau E., Guillemot D., Thiébaut A.C. Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: A meta-analysis of observational studies. BMC Infect. Dis. 2013; 13: 373.
  3. Давыдов М.И., Аксель Е.М. ред. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. М.: Издательская группа РОНЦ; 2014: 47. [Davydov M.I., Axel E.M., ed. Statistics of malignant neoplasms in Russia and CIS countries in 2012. Moscow: Publishing group RONTS; 2014: 47. (in Russian)]
  4. DiGiuseppe S., Keiffer T.R., Bienkowska-Haba M., Luszczek W., Guion L.G., Müller M., Sapp M. Topography of the human papillomavirus minor capsid protein L2 during vesicular trafficking of infectious entry. J. Virol. 2015; 89(20): 10442-52.
  5. Richart R.M. Cervical intraepithelial neoplasia. Pathol. Ann. 1973; 8: 301.
  6. World Health Organization. Human papillomavirus (HPV) and cervical cancer. Available at: http://www.who.int/mediacentre/factsheets/fs380/en/ Accessed 24 February 2016
  7. Stahlhut C., Slack F.J. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013; 5(12): 111.
  8. Frixa T., Donzelli S., Blandino G. Oncogenic MicroRNAs: Key players in malignant transformation. Cancers (Basel). 2015; 7(4): 2466-85.
  9. Galamb Á., Benczik M., Zinner B., Vigh E., Baghy K., Jeney C. et al. Dysregulation of microRNA expression in human cervical preneoplastic and neoplastic lesions. Pathol. Oncol. Res. 2015; 21(3): 503-8.
  10. Коган Е.А., Файзуллина Н.М., Ли Ц., Демура Т.А., Жарков Н.В., Козаченко А.В., Чернова В.Ф., Байрамова Г.Р., Прилепская В.Н. Ранняя диагностика ВПЧ-ассоциированной патологии шейки матки у женщин до 30 лет и старше. Акушерство и гинекология. 2015; 9: 62-7.
  11. Zhu X.L., Wen S.Y., Ai Z.H., Wang J., Xu Y.L., Teng Y.C. Screening for characteristic rnicroRNAs between pre-invasive and invasive stages of cervical cancer. Mol. Med. Rep. 2015; 12(1): 55-62.
  12. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T. et al. Realtirne quantification of rnicroRNAs by stern-loop RT-PCR. Nucleic Acids Res. 2005; 33(20): e179.
  13. López A.Y., López J.A. Multistep rnodel of cervical cancer: participation of rniR-NAs and coding genes. Int. J. Mol. Sci. 2014; 15(9): 15700-33.
  14. Байрамова Г.Р., Файзуллин Л.З., Королькова А.И., Полозников А.А., Киселев В.И. Скрининг рака шейки матки: что нового в мировой практике? Акушерство и гинекология. 2016; 7: 17-21. http://dx.doi. org/10.18565/aig.2016.7.17-21 [Bairarnova G.R., Faizullin L.Z., Korolkova A.I., Poloznikov A.A., Kiselev V.I. Cervical cancer screening: What is new in global practice? Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016; (7): 17-21. (in Russian) http://dx.doi.org/10.18565/aig.2016.717-21]
  15. Tian Q., Li Y, Wang F., Li Y., Xu J., Shen Y. et al. MicroRNA Detection in cervical exfoliated cells as a triage for human papillomavirus - positive women. J. Natl. Cancer Inst. 2014; 106(9): pii: dju241.
  16. Malta M., Ribeiro J., Monteiro P., Loureiro J., Medeiros R., Sousa H. Let-7c is a candidate biomarker for cervical intraepithelial lesions: a pilot study. Mol. Diagn. Ther. 2015; 19(3): 191-6.
  17. Xin M., Qiao Z., Li J., Liu J., Song S., Zhao X. et al. miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer. Oncotarget. 2016; 7(28): 44252-65.
  18. Song S.J., Pandolfl P.P. miR-22 in tumorigenesis. Cell Cycle. 2014; 13(1): 11-2.
  19. Zhang H., Cao H., Xu D., Zhu K. MicroRNA-92a promotes metastasis of nasopharyngeal carcinoma by targeting the PTEN/AKT pathway. Onco Targets Ther. 2016;9:3579-88.
  20. Caiazzfl C., Mallardo M. The roles of miR-25 and its targeted genes in development of human cancer. Microna. 2016; 5(2): 113-9.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##